Cui Yang1, Wanling Wang1, Youmei Zi1, Xiaolin Han1, Xiaoxue Qin1, Jingdong Li1, Honggang Ren2. 1. Department of Hematology, First Affiliated Hospital of Xinxiang Medical University 88 Jiankang Road, Weihui 453100, Henan Province, China. 2. Medical Center, Vanderbilt University School of Medicine Nashville, TN 37212, USA.
Abstract
OBJECTIVES: The tumor necrosis factor-α (TNF-α) gene, which plays crucial roles in tumorigenesis, is reported to be an independent marker for cancer. This study aims to examine the association between the TNF-α G308A polymorphism and DLBCL risk based on the two center case-control studies and meta-analysis. METHODS: In the current study, we performed a two centers case-control study to investigate the effect of the TNF-α G308A polymorphism on DLBCL risk in Chinese Han population. A meta-analysis including 10 published datasets along with current dataset, including 111 comparisons containing 34,041 cases and 42,730 controls were enrolled, was next performed to further confirm the association after literature search was conducted and relevant studies were identified from PubMed, Embase, and Web of Science. RESULTS: The TNF-α -308A allele was associated with a significantly increased DLBCL risk in the two independent patient case-control studies and additionally for pooled analysis from the two sets (P<0.05 for both). The result of meta-analysis further demonstrated that the A allele of -308A was significantly correlated with DLBCL risk under the allelic model (OR=1.35, 95% CI=1.27-1.44) without heterogeneity by fixed-effects model analysis (Q=17.30, P=0.139). Moreover, sensitivity analysis supported the robustness of this meta-analysis. CONCLUSION: This study suggested that -308A polymorphism may be associated with the susceptibility of DLBCL in a Chinese population. The further meta-analysis provides additional evidence supporting the above result that the risk allele of the -308A polymorphism may increase DLBCL risk.
OBJECTIVES: The tumor necrosis factor-α (TNF-α) gene, which plays crucial roles in tumorigenesis, is reported to be an independent marker for cancer. This study aims to examine the association between the TNF-α G308A polymorphism and DLBCL risk based on the two center case-control studies and meta-analysis. METHODS: In the current study, we performed a two centers case-control study to investigate the effect of the TNF-α G308A polymorphism on DLBCL risk in Chinese Han population. A meta-analysis including 10 published datasets along with current dataset, including 111 comparisons containing 34,041 cases and 42,730 controls were enrolled, was next performed to further confirm the association after literature search was conducted and relevant studies were identified from PubMed, Embase, and Web of Science. RESULTS: The TNF-α -308A allele was associated with a significantly increased DLBCL risk in the two independent patient case-control studies and additionally for pooled analysis from the two sets (P<0.05 for both). The result of meta-analysis further demonstrated that the A allele of -308A was significantly correlated with DLBCL risk under the allelic model (OR=1.35, 95% CI=1.27-1.44) without heterogeneity by fixed-effects model analysis (Q=17.30, P=0.139). Moreover, sensitivity analysis supported the robustness of this meta-analysis. CONCLUSION: This study suggested that -308A polymorphism may be associated with the susceptibility of DLBCL in a Chinese population. The further meta-analysis provides additional evidence supporting the above result that the risk allele of the -308A polymorphism may increase DLBCL risk.
Entities:
Keywords:
TNF-α; diffuse large B-cell lymphoma; polymorphism
Authors: René Scholtysik; Inga Nagel; Markus Kreuz; Inga Vater; Maciej Giefing; Carsten Schwaenen; Swen Wessendorf; Lorenz Trümper; Markus Loeffler; Reiner Siebert; Ralf Küppers Journal: Int J Cancer Date: 2012-01-31 Impact factor: 7.396
Authors: Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet Journal: Blood Date: 2005-09-08 Impact factor: 22.113
Authors: E Louis; D Franchimont; A Piron; Y Gevaert; N Schaaf-Lafontaine; S Roland; P Mahieu; M Malaise; D De Groote; R Louis; J Belaiche Journal: Clin Exp Immunol Date: 1998-09 Impact factor: 4.330
Authors: Pia Fernberg; Ellen T Chang; Kristina Duvefelt; Henrik Hjalgrim; Sandra Eloranta; Karina Meden Sørensen; Anna Porwit; Keith Humphreys; Mads Melbye; Karin Ekström Smedby Journal: Cancer Causes Control Date: 2010-01-20 Impact factor: 2.506
Authors: Lindsay M Morton; Sophia S Wang; Wendy Cozen; Martha S Linet; Nilanjan Chatterjee; Scott Davis; Richard K Severson; Joanne S Colt; Mohammad A Vasef; Nathaniel Rothman; Aaron Blair; Leslie Bernstein; Amanda J Cross; Anneclaire J De Roos; Eric A Engels; David W Hein; Deirdre A Hill; Linda E Kelemen; Unhee Lim; Charles F Lynch; Maryjean Schenk; Sholom Wacholder; Mary H Ward; Shelia Hoar Zahm; Stephen J Chanock; James R Cerhan; Patricia Hartge Journal: Blood Date: 2008-09-16 Impact factor: 22.113